Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray Compared to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 12 years;~* Acute pharyngitis or tonsillitis with symptoms of throat pain and inflammation of the pharynx and/or tonsils;~* Onset of sore throat less than 72 hours before inclusion ;~* A Tonsillopharyngitis Severity Score ≥6;~* Written informed consent.~Exclusion Criteria:~* Analgesics \<12 hours;~* Antibiotics \<24 hours; t~* Topical throat pain medication \<4 hours;~* Systemic corticosteroids within the last month;~* Symptoms of primary bacterial pharyngitis or secondary bacterial infection;~* Serious illness such as tumors; allergy to one of the ingredients; pregnancy or lactation;~* Hypersensitivity to ibuprofen;~* Participation in another clinical trial in the previous 30 days.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Drug: Echinacea/sage~patients received additionally a placebo-spray for the synthetical comparator (chlorhexidine/lidocaine) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.~Arms: 1
- 1 (Type: ACTIVE_COMPARATOR): Drug: Chlorhexidine/lidocaine~patients received additionally a placebo-spray for the synthetical comparator (echinacea/sage) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).